Published in Chem Biol on June 01, 1998
Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci U S A (1999) 5.28
A novel active site-directed probe specific for deubiquitylating enzymes reveals proteasome association of USP14. EMBO J (2001) 3.42
Chlamydia inhibits interferon gamma-inducible major histocompatibility complex class II expression by degradation of upstream stimulatory factor 1. J Exp Med (1999) 2.39
The ubiquitin-proteasome pathway and proteasome inhibitors. Med Res Rev (2001) 2.18
Specific and covalent targeting of conjugating and deconjugating enzymes of ubiquitin-like proteins. Mol Cell Biol (2004) 1.86
Global analysis of proteasomal substrate specificity using positional-scanning libraries of covalent inhibitors. Proc Natl Acad Sci U S A (2001) 1.58
Proteolytic Potential of the MSC Exosome Proteome: Implications for an Exosome-Mediated Delivery of Therapeutic Proteasome. Int J Proteomics (2012) 1.36
The ubiquitin-associated domain of hPLIC-2 interacts with the proteasome. Mol Biol Cell (2003) 1.32
Activity-based probes as a tool for functional proteomic analysis of proteases. Expert Rev Proteomics (2008) 1.26
Cysteine protease inhibitors as chemotherapy: lessons from a parasite target. Proc Natl Acad Sci U S A (1999) 1.23
The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- or down-regulate antigen presentation at nontoxic doses. J Immunol (2000) 1.20
Small-molecule control of intracellular protein levels through modulation of the ubiquitin proteasome system. Angew Chem Int Ed Engl (2014) 1.18
Integration of the ubiquitin-proteasome pathway with a cytosolic oligopeptidase activity. Proc Natl Acad Sci U S A (2000) 1.07
Cysteine protease inhibitors block Toxoplasma gondii microneme secretion and cell invasion. Antimicrob Agents Chemother (2006) 1.06
From bortezomib to other inhibitors of the proteasome and beyond. Curr Pharm Des (2013) 1.04
Lysine 188 substitutions convert the pattern of proteasome activation by REGgamma to that of REGs alpha and beta. EMBO J (2001) 1.02
Bivalency as a principle for proteasome inhibition. Proc Natl Acad Sci U S A (1999) 0.96
Identification of the proteasome inhibitor MG262 as a potent ATP-dependent inhibitor of the Salmonella enterica serovar Typhimurium Lon protease. Biochemistry (2006) 0.90
A panel of subunit-selective activity-based proteasome probes. Org Biomol Chem (2010) 0.89
Development and characterization of proteasome inhibitors. Methods Enzymol (2005) 0.87
A mathematical model of protein degradation by the proteasome. Biophys J (2005) 0.87
Simplified synthetic TMC-95A/B analogues retain the potency of proteasome inhibitory activity. Chembiochem (2003) 0.86
Multiplexed metagenome mining using short DNA sequence tags facilitates targeted discovery of epoxyketone proteasome inhibitors. Proc Natl Acad Sci U S A (2015) 0.85
Chemical genetics: exploring the role of the proteasome in cell biology using natural products and other small molecule proteasome inhibitors. J Med Chem (2008) 0.85
Characterization of peptidyl boronic acid inhibitors of mammalian 20 S and 26 S proteasomes and their inhibition of proteasomes in cultured cells. Biochem J (2000) 0.85
Trypanocidal activities of trileucine methyl vinyl sulfone proteasome inhibitors. Parasitol Res (2004) 0.83
Discovery of a potent and highly β1 specific proteasome inhibitor from a focused library of urea-containing peptide vinyl sulfones and peptide epoxyketones. Org Biomol Chem (2011) 0.81
Activity-based imaging probes of the proteasome. Cell Biochem Biophys (2013) 0.79
Peptide and Peptide-Like Modulators of 20S Proteasome Enzymatic Activity in Cancer Cells. Int J Pept Res Ther (2006) 0.77
Evaluation of alpha,beta-unsaturated ketone-based probes for papain-family cysteine proteases. Bioorg Med Chem (2008) 0.77
Harnessing proteasome dynamics and allostery in drug design. Antioxid Redox Signal (2014) 0.75
The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol. Cell (1996) 8.25
Sec61-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction. Nature (1996) 7.90
Segregation of MHC class II molecules from MHC class I molecules in the Golgi complex for transport to lysosomal compartments. Nature (1991) 5.90
Major histocompatibility antigens: the human (HLA-A, -B, -C) and murine (H-2K, H-2D) class I molecules. Cell (1981) 5.81
The dilemma of MDR-TB in the global era. Int J Tuberc Lung Dis (1998) 5.77
Viral subversion of the immune system. Annu Rev Immunol (2000) 5.76
TAP1 mutant mice are deficient in antigen presentation, surface class I molecules, and CD4-8+ T cells. Cell (1992) 4.76
Quorum sensing controls expression of the type III secretion gene transcription and protein secretion in enterohemorrhagic and enteropathogenic Escherichia coli. Proc Natl Acad Sci U S A (1999) 4.42
Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. J Immunol (1986) 4.30
The biosynthetic pathway of MHC class II but not class I molecules intersects the endocytic route. Cell (1990) 4.18
Isolation and characterization of the intracellular MHC class II compartment. Nature (1994) 3.50
Direct binding of peptide to empty MHC class I molecules on intact cells and in vitro. Cell (1990) 3.44
A novel active site-directed probe specific for deubiquitylating enzymes reveals proteasome association of USP14. EMBO J (2001) 3.42
Uvomorulin: a nonintegral membrane protein of early mouse embryo. Proc Natl Acad Sci U S A (1983) 3.42
Timely diagnosis of MDR-TB under program conditions: is rapid drug susceptibility testing sufficient? Int J Tuberc Lung Dis (2006) 3.34
Cell-free translation of the mRNAs for the heavy and light chains of HLA-A and HLA-B antigens. Proc Natl Acad Sci U S A (1979) 3.29
The locus of enterocyte effacement (LEE)-encoded regulator controls expression of both LEE- and non-LEE-encoded virulence factors in enteropathogenic and enterohemorrhagic Escherichia coli. Infect Immun (2000) 3.20
Human cytomegalovirus US3 impairs transport and maturation of major histocompatibility complex class I heavy chains. Proc Natl Acad Sci U S A (1996) 3.17
The human beta 2-microglobulin gene. Primary structure and definition of the transcriptional unit. J Immunol (1987) 3.09
Cathepsin S required for normal MHC class II peptide loading and germinal center development. Immunity (1999) 3.01
Molecular cloning of a human histocompatibility antigen cDNA fragment. Proc Natl Acad Sci U S A (1980) 2.99
Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading. Immunity (1996) 2.93
The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP. Immunity (1997) 2.93
Covalent modification of the active site threonine of proteasomal beta subunits and the Escherichia coli homolog HslV by a new class of inhibitors. Proc Natl Acad Sci U S A (1997) 2.81
Cathepsins B and D are dispensable for major histocompatibility complex class II-mediated antigen presentation. Proc Natl Acad Sci U S A (1998) 2.75
Interference with HIV-induced syncytium formation and viral infectivity by inhibitors of trimming glucosidase. Nature (1987) 2.72
Giant Rashba-type spin splitting in bulk BiTeI. Nat Mater (2011) 2.49
TAP1-dependent peptide translocation in vitro is ATP dependent and peptide selective. Cell (1993) 2.43
Human cytomegalovirus down-regulates HLA class I expression by reducing the stability of class I H chains. J Immunol (1993) 2.40
The WD-40 repeat. FEBS Lett (1992) 2.37
The inhomogeneous structure of water at ambient conditions. Proc Natl Acad Sci U S A (2009) 2.31
Stable binding of the herpes simplex virus ICP47 protein to the peptide binding site of TAP. EMBO J (1996) 2.26
Secreted cathepsin L generates endostatin from collagen XVIII. EMBO J (2000) 2.24
How MHC class II molecules acquire peptide cargo: biosynthesis and trafficking through the endocytic pathway. Annu Rev Cell Dev Biol (1995) 2.24
The alpha chain of the T cell antigen receptor is degraded in the cytosol. Immunity (1997) 2.20
Dislocation of type I membrane proteins from the ER to the cytosol is sensitive to changes in redox potential. J Cell Biol (1998) 2.16
HLA-A- and HLA-B-specific monoclonal antibodies reactive with free heavy chains in western blots, in formalin-fixed, paraffin-embedded tissue sections and in cryo-immuno-electron microscopy. Int Immunol (1990) 2.12
Allele and locus-specific differences in cell surface expression and the association of HLA class I heavy chain with beta 2-microglobulin: differential effects of inhibition of glycosylation on class I subunit association. Eur J Immunol (1988) 2.03
Peptide selection by MHC class I molecules. Nature (1991) 2.01
Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer Res (1994) 1.99
A mouse cytomegalovirus glycoprotein, gp34, forms a complex with folded class I MHC molecules in the ER which is not retained but is transported to the cell surface. EMBO J (1997) 1.98
Peptide contributes to the specificity of positive selection of CD8+ T cells in the thymus. Cell (1993) 1.96
Comparison of amino acid sequences of two human histocompatibility antigens, HLA-A2 and HLA-B7: location of putative alloantigenic sites. Proc Natl Acad Sci U S A (1979) 1.94
Biosynthesis and cell surface localization of nonglycosylated human histocompatibility antigens. J Immunol (1981) 1.91
Epithelial cell polarity affects susceptibility to Pseudomonas aeruginosa invasion and cytotoxicity. Infect Immun (1997) 1.90
How MHC class II molecules reach the endocytic pathway. EMBO J (1995) 1.80
Major histocompatibility class I presentation of soluble antigen facilitated by Mycobacterium tuberculosis infection. Proc Natl Acad Sci U S A (1996) 1.76
Cathepsin S activity regulates antigen presentation and immunity. J Clin Invest (1998) 1.76
A proteolytic system that compensates for loss of proteasome function. Nature (1998) 1.76
The pathway of US11-dependent degradation of MHC class I heavy chains involves a ubiquitin-conjugated intermediate. J Cell Biol (1999) 1.74
Peptide length and sequence specificity of the mouse TAP1/TAP2 translocator. J Exp Med (1994) 1.73
Peptide translocation by variants of the transporter associated with antigen processing. Science (1993) 1.71
Comparison of tilmicosin with long-acting oxytetracycline for treatment of respiratory tract disease in calves. J Am Vet Med Assoc (1996) 1.70
Polyubiquitination is required for US11-dependent movement of MHC class I heavy chain from endoplasmic reticulum into cytosol. Mol Biol Cell (2001) 1.69
Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J Exp Med (1994) 1.69
An improved biochemical method for the analysis of HLA-class I antigens. Definition of new HLA-class I subtypes. Hum Immunol (1986) 1.67
Global regulatory mutations in csrA and rpoS cause severe central carbon stress in Escherichia coli in the presence of acetate. J Bacteriol (2000) 1.67
Psychiatric issues in the management of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis (2004) 1.65
Acetate metabolism in a pta mutant of Escherichia coli W3110: importance of maintaining acetyl coenzyme A flux for growth and survival. J Bacteriol (1999) 1.62
Abnormally high expression of proteasomes in human leukemic cells. Proc Natl Acad Sci U S A (1990) 1.62
Plant thioredoxin h: an animal-like thioredoxin occurring in multiple cell compartments. Arch Biochem Biophys (1991) 1.62
Antigen presentation subverted: Structure of the human cytomegalovirus protein US2 bound to the class I molecule HLA-A2. Proc Natl Acad Sci U S A (2001) 1.60
Clinical appearances, healing patterns, risk factors, and outcomes of horses with fungal keratitis: 53 cases (1978-1996) J Am Vet Med Assoc (1998) 1.59
A myristoylated pseudosubstrate peptide, a novel protein kinase C inhibitor. J Biol Chem (1993) 1.58
Cathepsin S controls the trafficking and maturation of MHC class II molecules in dendritic cells. J Cell Biol (1999) 1.58
Major histocompatibility complex class II compartments in human B lymphoblastoid cells are distinct from early endosomes. J Exp Med (1995) 1.57
Use of HLA loss mutants to analyse the structure of the human major histocompatibility complex. Nature (1982) 1.56
Proteases involved in MHC class II antigen presentation. Immunol Rev (1999) 1.54
Extended peptide-based inhibitors efficiently target the proteasome and reveal overlapping specificities of the catalytic beta-subunits. Chem Biol (2001) 1.52
The HCMV gene products US11 and US2 differ in their ability to attack allelic forms of murine major histocompatibility complex (MHC) class I heavy chains. J Exp Med (1997) 1.51
Peptide loading of empty major histocompatibility complex molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte responses. Eur J Immunol (1991) 1.51
Role for cathepsin F in invariant chain processing and major histocompatibility complex class II peptide loading by macrophages. J Exp Med (2000) 1.49
Efficacy of interferon alfa therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level. Hepatology (1995) 1.47
Peptide antagonism and T cell receptor interactions with peptide-MHC complexes. Immunity (1998) 1.46
Purification, cDNA-cloning and expression of human diacylglycerol kinase. FEBS Lett (1990) 1.45
In vitro translation and assembly of a complete T cell receptor-CD3 complex. J Exp Med (1997) 1.45
Isolation, expression, and the primary structure of HLA-Cw1 and HLA-Cw2 genes: evolutionary aspects. Immunogenetics (1987) 1.41
Cell-free synthesis and processing of the heavy and light chains of HLA-DR antigens. J Exp Med (1980) 1.39
Release of signal peptide fragments into the cytosol requires cleavage in the transmembrane region by a protease activity that is specifically blocked by a novel cysteine protease inhibitor. J Biol Chem (2000) 1.38
Peptide influences the folding and intracellular transport of free major histocompatibility complex class I heavy chains. J Exp Med (1995) 1.38
Assembly of HLA DR1 molecules translated in vitro: binding of peptide in the endoplasmic reticulum precludes association with invariant chain. EMBO J (1994) 1.37
The cytosolic tail of class I MHC heavy chain is required for its dislocation by the human cytomegalovirus US2 and US11 gene products. Proc Natl Acad Sci U S A (1999) 1.35
N-linked glycan modification on antigen-presenting cells restores an allospecific cytotoxic T cell response. J Exp Med (1990) 1.34
Mitotic separation of two human X-linked genes in man--mouse somatic cell hybrids. Proc Natl Acad Sci U S A (1971) 1.33
Mapping functional regions in the lumenal domain of the class II-associated invariant chain. J Exp Med (1994) 1.32
Proteolysis in MHC class II antigen presentation: who's in charge? Immunity (2000) 1.32
Evidence from opiate binding studies that heroin acts through its metabolites. Life Sci (1983) 1.30
Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene. Cancer Epidemiol Biomarkers Prev (1994) 1.30
Mechanisms of induction of primary virus-specific cytotoxic T lymphocyte responses. Eur J Immunol (1992) 1.30
Nurses as providers of emotional support to patients with MDR-TB. Int Nurs Rev (2006) 1.30
Programmatic management of multidrug-resistant tuberculosis: models from three countries. Int J Tuberc Lung Dis (2011) 1.29
Why certain antibodies cross-react with HLA-A and HLA-G: epitope mapping of two common MHC class I reagents. Mol Immunol (1998) 1.29
Altered natural killer cell repertoire in Tap-1 mutant mice. Proc Natl Acad Sci U S A (1994) 1.28
Molecular cloning of cDNA for proteasomes (multicatalytic proteinase complexes) from rat liver: primary structure of the largest component (C2). Biochemistry (1989) 1.27
Degradation of mouse invariant chain: roles of cathepsins S and D and the influence of major histocompatibility complex polymorphism. J Exp Med (1997) 1.25
Involvement of the vacuolar H(+)-ATPases in the secretory pathway of HepG2 cells. J Biol Chem (1993) 1.25
Intracellular transport of MHC class II molecules. Immunol Today (1992) 1.24